Vaxcyte, Inc.
PCVX
$44.70
-$0.82-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 226.16% |
| Gross Profit | -- | -- | -- | -- | -226.16% |
| SG&A Expenses | 53.53% | 56.05% | 56.62% | 53.05% | 48.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.35% | 22.86% | 24.36% | 21.69% | 68.76% |
| Operating Income | -34.35% | -22.86% | -24.36% | -21.69% | -68.76% |
| Income Before Tax | -29.46% | -10.12% | -16.67% | -15.33% | -69.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.46% | -10.12% | -16.67% | -15.33% | -69.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.46% | -10.12% | -16.67% | -15.33% | -69.49% |
| EBIT | -34.35% | -22.86% | -24.36% | -21.69% | -68.76% |
| EBITDA | -33.52% | -21.90% | -23.44% | -21.01% | -68.75% |
| EPS Basic | -6.44% | 11.12% | 5.69% | 6.81% | -37.84% |
| Normalized Basic EPS | -6.43% | 11.12% | 5.69% | 6.81% | -37.87% |
| EPS Diluted | -6.44% | 11.12% | 5.69% | 6.81% | -37.84% |
| Normalized Diluted EPS | -6.43% | 11.12% | 5.69% | 6.81% | -37.87% |
| Average Basic Shares Outstanding | 19.32% | 22.50% | 23.65% | 25.58% | 24.72% |
| Average Diluted Shares Outstanding | 19.32% | 22.50% | 23.65% | 25.58% | 24.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |